



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

## Cambridge Heart, Inc

[View the current Cambridge Heart, Inc Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/20333-Cambridge+Heart%2C+Inc.html)

(<http://www.bioportfolio.com/biocorporate/20333-Cambridge+Heart%2C+Inc.html>)

### Contact Details:

**1 Oak Park Drive  
Bedford  
Massachusetts  
01730  
United States of America**

Tel: 781-271-1200  
Fax: 781-275-8431  
Email: [alternans@cambridgeheart.com](mailto:alternans@cambridgeheart.com)

Cambridge Heart is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, we are addressing a key problem in cardiac diagnosis-the identification of those at risk of sudden cardiac death. Sudden cardiac arrest accounts for approximately one third of all cardiac deaths, or over 400,000 deaths, in the United States each year. Our diagnostic products incorporate our proprietary technology for the measurement of Microvolt T-Wave Alternans (MTWA). Microvolt T-Wave Alternans is an extremely subtle beat-to-beat fluctuation in the T-wave segment of a patient's heartbeat. The use of our products and technology in the performance of a Microvolt T-Wave Alternans Test can detect these tiny heartbeat variations, measured down to one millionth of a volt.

A wide range of published clinical data has shown that patients with symptoms of or at risk of life threatening arrhythmias who have a normal or negative MTWA test are at minimal risk for a sudden cardiac event while those who have an abnormal or positive test are at increased risk for subsequent sudden cardiac events including sudden death. We believe that this data demonstrates that our Microvolt T-Wave Alternans technology is the only non-invasive test comparable or superior to the invasive "gold standard" electrophysiology study in the prediction of sudden death.

### Press Releases on Cambridge Heart, Inc:

[First Live Case in the U.K.  
Using Cappella's  
Sideguard\(R\) Coronary  
Sidebranch Stent at PCI  
Live](#)

25th November,  
2009

*GALWAY, Ireland, November 25  
/PRNewswire/ -- Cappella, Inc.  
(Cappella), a medical device  
company developing dynamic  
solutions for the treatment of  
coronary bifurcation disease  
announced the first U.K.*

[Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference](#)

24th November, 2009

Accumetrics, Inc.

SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual

[ATS Medical to Participate in the 21st Annual Piper Jaffray Health Care Conference](#)

24th November, 2009

ATS Medical, Inc.

MINNEAPOLIS, Nov. 24 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products, announced today that it will participate in the

[National Certification for Medical Interpreters Launched in the US](#)

24th November, 2009

International Medical Interpreters Association

WASHINGTON, Nov. 24 /PRNewswire/ -- Patients in the United States with limited English proficiency (LEP) continue to face language barriers that threaten their health and undermine their well-being.

[Shire Submits European Marketing Authorization Application \(MAA\) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease](#)

24th November, 2009

DUBLIN, November 24 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency

## BioNews Results for Cambridge Heart, Inc



- [Study Supports Use Of MTWA Test As Predictor Of Sudden Cardiac Death](#)  
*Medical News Today: Nov 19 2009 8:23PM Matching: cambridge heart inc*
- [Medical News: Study Supports Use Of MTWA Test As Predictor Of Sudden Cardiac Death](#)  
*BioFind: Nov 19 2009 5:49PM Matching: cambridge heart inc*
- [Study Supports Use of MTWA Test as Predictor of Sudden Cardiac Death](#)  
*Genetic Engineering News: Nov 18 2009 3:21PM Matching: cambridge heart inc*
- [Cambridge Heart Reports Results for the Third Quarter 2009](#)  
*SmartBrief: Nov 17 2009 12:03AM Matching: cambridge heart inc*
- [Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA](#)  
*Reuters: Nov 17 2009 3:52PM Matching: cambridge heart inc*
- [Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA](#)  
*Street Insider: Nov 17 2009 2:57PM Matching: cambridge heart inc*

- [Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA Business Wire via Yahoo!](#): Nov 17 2009 4:03PM Matching: cambridge heart inc
- [Cambridge Heart announces financial results for the third quarter of 2009](#) News-Medical.Net: Nov 16 2009 2:42PM Matching: cambridge heart inc
- [Two Key Cardiac Monitoring Companies to Expand Stress Test Capabilities](#) Diagnostic & Invasive Cardiology: Nov 14 2009 2:10AM Matching: cambridge heart inc
- [Cardiac Science and Cambridge Heart team up to develop MTWA module](#) News-Medical.Net: Nov 13 2009 7:23AM Matching: cambridge heart inc
- [Molecular Insight Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new](#) PR inside: Nov 13 2009 3:07PM Matching: cambridge heart inc
- [Cardiac Science and Cambridge Heart Announce Development Partnership](#) Freshnews.com: Nov 12 2009 2:20PM Matching: cambridge heart inc
- [Cambridge Heart, Cardiac Science Form Development Partnership](#) FDA News: Nov 12 2009 10:39PM Matching: cambridge heart inc
- [BioMed Realty Trust signs a ten-year lease with Broad Institute in Cambridge](#) News-Medical.Net: Oct 29 2009 8:45AM Matching: cambridge heart inc

## Cambridge Heart, Inc Patents:



- 7435223- [Identifying infants at risk for sudden infant death syndrome](#)
- 5673702- [Method and apparatus for the improved electronic display of physiologic waveforms](#)
- 5704365- [Using related signals to reduce ECG noise](#)
- 5713367- [Measuring and assessing cardiac electrical stability](#)
- 5724984- [Multi-segment ECG electrode and system](#)
- 5791944- [Electrode connector](#)
- 5827195- [Electrocardiogram noise reduction using multi-dimensional filtering](#)
- 5891045- [Method and system for obtaining a localized cardiac measure](#)
- 5891047- [Detecting abnormal activation of heart](#)
- 5908393- [Reducing noise in a biological signal](#)
- 5935082- [Assessing cardiac electrical stability](#)
- 6047206- [Generation of localized cardiac measures](#)
- 6253107- [Cardiac pacing to induce heart rate variability](#)
- 6453191- [Automated interpretation of T-wave alternans results](#)
- 6735466- [Analytical signal method for analysis of T-wave alternans](#)
- 7197358- [Identifying infants at risk for sudden infant death syndrome](#)
- 5570696- [Method and apparatus for assessing myocardial electrical stability](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

